DRUG: Sofosbuvir, velpatasvir and voxilaprevir
Entry
D10900 Mixture Drug
Name
Sofosbuvir, velpatasvir and voxilaprevir;
Vosevi (TN)
Product
VOSEVI (Gilead Sciences)
Component
Sofosbuvir [DR:
D10366
], Velpatasvir [DR:
D10806
], Voxilaprevir [DR:
D10899
]
Remark
ATC code:
J05AP56
Product:
D10900<US>
Efficacy
Antiviral
Disease
Chronic hepatitis C virus infection [DS:
H00413
]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:
br08303
]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AP Antivirals for treatment of HCV infections
J05AP56 Sofosbuvir, velpatasvir and voxilaprevir
D10900 Sofosbuvir, velpatasvir and voxilaprevir <US>
USP drug classification [BR:
br08302
]
Antivirals
Anti-hepatitis C (HCV) Agents
Sofosbuvir/ Velpatasvir/ Voxilaprevir
D10900 Sofosbuvir, velpatasvir and voxilaprevir
Antiinfectives [
br08350.html
]
Antivirals
D10900
New drug approvals in the USA [
br08319.html
]
New molecular entities and new therapeutic biological products
D10900
New drug approvals in Europe [
br08329.html
]
European public assessment reports (EPAR) authorised medicine
D10900
New drug approvals in the USA, Europe and Japan [
br08328.html
]
Approval dates by FDA, EMA and PMDA
D10900
Other DBs
PubChem:
340650304
LinkDB
» Japanese version
» Back
DBGET
integrated database retrieval system
